Celgene multiple myeloma IMiD Pomalyst OK'd in US
This article was originally published in Scrip
Executive Summary
Patients with the blood cancer multiple myeloma are suddenly finding themselves with more options to treat their disease, with Celgene's new medicine Pomalyst (pomalidomide) the latest to be entering the US market after gaining an accelerated approval from the US FDA's on 8 February.